Cantargia
1.92
SEK
-35.57 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1,314 following
cantargia.com
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CANTA
Daily low / high price
1.883 / 2.08
SEK
Market cap
352.68M SEK
Turnover
4.62M SEK
Volume
2.4M
Latest videos
Financial calendar
Interim report
15.11.2024
Extraordinary general meeting
02.12.2024
Annual report
21.02.2025
Interim report
13.05.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.9 % | 9.9 % |
Första AP-Fonden | 7.1 % | 7.1 % |
Alecta Pensionsförsäkring, Ömsesidigt | 7.0 % | 7.0 % |
Six Sis AG | 4.7 % | 4.7 % |
Försäkringsaktiebolaget, Avanza Pension | 4.4 % | 4.4 % |
Goldman Sachs International | 3.4 % | 3.4 % |
Handelsbanken fonder | 3.2 % | 3.2 % |
Swedbank Robur Fonder | 2.0 % | 2.0 % |
Brushamn Invest | 1.2 % | 1.2 % |
Prioritet Finans | 1.1 % | 1.1 % |
ShowingAll content types
Cantargia, Audiocast with teleconference, Q3'24
Notice of extraordinary general meeting in Cantargia AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools